References
- Olanzi A, Bennet JM, Germing U, et al. Chronic myelomonocytic leukemia. In: Swerdlow SH, Campo E, Harris NL et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp 76–79.
- Such E, Cervera J, Costa D, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011;96: 375–383.
- Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 2013;121:3005–3015.
- Mallo M, Arenillas L, Espinet B, et al. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica 2008;93:1001–1008.
- Ademà V, Hernández JM, Abáigar M, et al. Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?Leuk Res 2013;37:416–421.
- Shaffer L, Slovak M, Campbell U. An international system for human cytogenetic nomenclature 2009. Basel: S Karger; 2009.
- Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007;109:2399–2405.
- Youssef SR, Ismail MM, Abd Al Wahed E, et al. Growth advantage of CD34 + cells in trisomy 8 high-risk myelodysplastic syndrome despite enhanced apoptotic signals. East Mediterr Health J 2012;18: 1065–1071.